Asset profile
LY03017
Small molecule
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
Also in development:Schizophrenia · Phase 1Parkinson's Disease · Phase 1
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
180 competitors in this universe: 4 direct rivals (same mechanism and indication), 2 same-class, 174 same-indication; 180 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| LY03017: this drug | Phase 1 | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist), 5-HT2A/2C receptor, 5-HT2A/5-HT2C | ||
| Pimavanserin (Nuplazid) | Approved | Small molecule | 5-HT2A/2C receptor, Serotonin 5-HT2A receptor (antagonist / inverse agonist) | ||
| ACP-204 | Phase 3 | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist) | ||
| Roluperidone | Phase 3 | Small molecule | Sigma-2 receptor complex, Serotonin 5-HT2A receptor (antagonist / inverse agonist) | ||
| Deramciclane | Phase 2/3 | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist) | ||
| Anplag Tab | Phase 3 | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist) | ||
| Sarpogrelate (Anplag) | Phase 3 | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist) | ||
| Amantadine ER (Gocovri / ADS-5102) | Approved | Small molecule | NMDA receptor | ||
| Apomorphine (Apokyn) | Approved | Small molecule | dopamine | ||
| Apomorphine Sublingual Film (Kynmobi) | Approved | Small molecule | dopamine | ||
| Aripiprazole (Abilify Maintena) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 receptor (partial agonist) | ||
| Aripiprazole (Abilify MyCite) | Approved | Combination | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist) | ||
| Aripiprazole (Abilify) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Aripiprazole Lauroxil (Aristada Initio) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Aripiprazole Lauroxil (Aristada) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Asenapine | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) |
…and 165 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.